| Entry |
|
|---|
| Name |
Saxagliptin hydrate (JAN);
Onglyza (TN) |
|---|
| Formula |
C18H25N3O2. H2O
|
|---|
| Exact mass |
333.2052
|
|---|
| Mol weight |
333.4253
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Antidiabetic agent
DG02044 Hypoglycemic agent
DG01601 DPP-4 inhibitor
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG02925 CYP3A5 substrate
|
|---|
| Remark |
| Therapeutic category: | 3969 |
| Product (DG00119): | D09753<JP> D10262<US> |
| Product (mixture): | D10826<US> |
|
|---|
| Efficacy |
Antidiabetic, Dipeptidyl peptidase-4 (DPP-4) inhibitor |
|---|
| Comment |
Treatment of type II diabetes mellitus and metabolic syndrome
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04974 | Protein digestion and absorption |
|
|---|
| Metabolism |
Enzyme: CYP3A4 [HSA: 1576], CYP3A5 [HSA: 1577]
|
|---|
| Interaction |
|
|---|
| Structure map |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
A ALIMENTARY TRACT AND METABOLISM
A10 DRUGS USED IN DIABETES
A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10BH Dipeptidyl peptidase 4 (DPP-4) inhibitors
A10BH03 Saxagliptin
D09753 Saxagliptin hydrate (JAN) <JP>
USP drug classification [BR:br08302]
Blood Glucose Regulators
Antidiabetic Agents
Dipeptidyl Peptidase-4 (DPP-4) Inhibitor
Saxagliptin
D09753 Saxagliptin hydrate (JAN)
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
396 Antidiabetic agents
3969 Others
D09753 Saxagliptin hydrate (JAN)
Drug groups [BR:br08330]
Antidiabetic agent
DG02044 Hypoglycemic agent
DG01601 DPP-4 inhibitor
DG00119 Saxagliptin
D09753 Saxagliptin hydrate
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00119 Saxagliptin
D09753 Saxagliptin hydrate
DG02925 CYP3A5 substrate
DG00119 Saxagliptin
D09753 Saxagliptin hydrate
Drug classes [BR:br08332]
Antidiabetic agent
DG01601 DPP-4 inhibitor
D09753 Saxagliptin hydrate
DG02044 Hypoglycemic agent
D09753 Saxagliptin hydrate
Target-based classification of drugs [BR:br08310]
Enzymes
Hydrolases (EC3)
Peptidyl-peptidases
DPP4 (CD26)
D09753 Saxagliptin hydrate (JAN) <JP>
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D09753
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D09753
Drug groups [BR:br08330]
Antidiabetic agent
DG02044 Hypoglycemic agent
DG01601 DPP-4 inhibitor
DG00119 Saxagliptin
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00119 Saxagliptin
DG02925 CYP3A5 substrate
DG00119 Saxagliptin
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 24
1 C1z C 23.3800 -20.7900
2 C1x C 22.6800 -22.1900
3 C1y C 22.6800 -23.4500
4 C1y C 22.1900 -22.7500
5 C1z C 24.5000 -22.7500
6 C1x C 21.1400 -23.8700
7 C1x C 23.8000 -24.4300
8 C1x C 22.1900 -21.4200
9 C1x C 23.3800 -23.3800
10 C1x C 24.5000 -21.4200
11 C1c C 23.3800 -19.3900
12 C5a C 24.5700 -18.7600
13 N1a N 22.1900 -18.7600
14 N1y N 25.7600 -19.3900
15 O5a O 24.5700 -17.3600
16 C1y C 26.1800 -20.7200
17 C1y C 27.5800 -20.7200
18 C1x C 28.0000 -19.3200
19 C1y C 26.8100 -18.6200
20 C3b C 26.8100 -17.2200
21 N3a N 26.8100 -15.8200
22 O1a O 25.8300 -22.7500
23 C1x C 26.8800 -21.9100
24 O0 O 29.1200 -24.3600
BOND 27
1 1 2 1
2 2 3 1
3 8 4 1
4 4 9 1
5 9 5 1
6 5 10 1
7 10 1 1
8 1 8 1
9 3 6 1
10 3 7 1
11 4 6 1
12 5 7 1
13 1 11 1
14 11 12 1
15 11 13 1 #Down
16 12 14 1
17 12 15 2
18 14 16 1
19 16 17 1
20 17 18 1
21 18 19 1
22 14 19 1
23 19 20 1 #Down
24 20 21 3
25 5 22 1
26 17 23 1
27 23 16 1
|
|---|
